ClinicalTrials.gg
CompletedNCT04268628EXPLOREUpdated Jan 3, 2022

A Study of Pharmacodynamic and Genetic Parameters of Abira-DES Study Participants (NCT02217566) - Participants With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Following Unresponsive Treatment With Diethylstilbestrol

An observational study in Metastatic Castration-resistant Prostate Cancer, sponsored by Janssen-Cilag Farmaceutica Ltda.. Completed at 1 site in Brazil. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-03.

Sponsored by Janssen-Cilag Farmaceutica Ltda. (part of Johnson & Johnson) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
42
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 88 studies in Prostatic Neoplasms by Johnson & Johnson — 9 open to participants now, 23 under way, 9 of them phase 3. Prostatic Neoplasms · Johnson & Johnson.

Enrollment
13th of 16
42 · median 300
Started
2020
with 6 others
Observational
16 of 88
1 open now
Registered
64th of 88
by date

Among the 88 studies in Prostatic Neoplasms by Johnson & Johnson, this one is the 13th largest by enrollment of the 16 observational ones that give a count, is one of 7 that started in 2020, is one of 16 observational ones, and was the 64th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

9 of the 88 studies in Prostatic Neoplasms by Johnson & Johnson are open now, in 8 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Prostatic Neoplasms by Johnson & Johnson, or all of them as a file.
02

Study summary

The primary purpose of this study is to evaluate the influence of HSD3B1 (1245C) germline variant and potential pharmacodynamic markers on abiraterone activity in participants with metastatic castration-resistant prostate cancer after unresponsive use of diethylstilbestrol.

03

Conditions studied

  • Metastatic Castration-resistant Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The population of this study comprised of participants with metastatic castration-resistant prostate cancer with disease progression following the use of diethylstilbestrol (DES) who participated in the Abira-DES study (NCT02217566) in which they were treated with abiraterone acetate.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have a confirmed diagnosis of prostate adenocarcinoma without neuroendocrine or small cell differentiation and was a participant in the Abira-DES study (NCT0221756), which includes: diethylstilbestrol pretreatment for castration-resistant prostate cancer with evidence of disease progression or grade 3/4 toxicity with diethylstilbestrol; disease confirmed by bone examination or metastatic lesions by computed tomography or magnetic resonance
  • Abiraterone acetate therapy during the Abira-DES study (NCT0221756), and peripheral blood samples have been collected from at least of the three proposed study timepoints
  • Must sign, and/or his/her legally acceptable representatives, where applicable, must sign the ICF allowing the use of clinical data and biological samples in accordance with local requirements. For deceased participants who did not provide consent prior to death, permission to research their information must meet local requirements

Exclusion criteria

Exclusion Criteria:

  • Having withdrawn the consent to use the samples collected during their participation in the Abira-DES study (NCT02217566)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
42 participants (actual)
Patient registry
No

Groups and cohorts

  • Participants with mCRPC

    Participants with metastatic castration resistant prostate cancer (mCRPC) will be evaluated for genetic polymorphism and pharmacodynamic parameters from serum and plasma samples collected during the Abira-DES study (NCT02217566). Serum and plasma samples were collected after use of diethylstilbestrol (DES) and subsequent abiraterone acetate therapy. Peripheral blood samples were collected prior to initiation of abiraterone acetate therapy, after 12 weeks of therapy, and at the time of disease progression (evaluated by prostate specific antigen \[PSA\] response).

    Other: Serum and plasma samples analysis

Interventions

  • OtherSerum and plasma samples analysis

    This is a non-interventional study and no drug will be given as part of this study. Serum and plasma samples will be collected from the participants with metastatic castration-resistant prostate cancer to evaluate genetic polymorphism and pharmacodynamic parameters.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with and Without HSD3B1 (1245C) Germline Variant'

    Percentage of participants with and without HSD3B1 (1245C) germline variant will be determined to evaluate the influence of HSD3B1 (1245C) germline variant on the response to abiraterone as a predictive fact.

    Time frame: Up to 12 months

Secondary outcomes

  1. Levels of HSD3B1 (1245C) Germ Variant

    Levels of HSD3B1 (1245C) germline variant will be determined to evaluate the response to abiraterone acetate as a predictive factor.

    Time frame: Up to 12 months

  2. Levels of Metabolite Delta-(4)-Abiraterone (D4A) During the Abiraterone Acetate During Treatment Phase

    Levels of metabolite D4A during the abiraterone acetate during treatment phase will be evaluated.

    Time frame: 12 Weeks

  3. Testosterone Levels in Participants Treated with Abiraterone Acetate

    Testosterone levels of participants treated with abiraterone acetate will be evaluated by the molecular analyses.

    Time frame: Up to 12 months

  4. SDHEA Levels in Participants Treated with Abiraterone Acetate

    SDHEA levels of participants treated with abiraterone acetate will be evaluated by the molecular analyses.

    Time frame: Up to 12 months

  5. Correlation Between HSD3B1 (1245C) Variant and Testosterone Levels

    Correlation between HSD3B1 (1245C) variant and testosterone levels will be reported. The genotyping of the HSD3B1 (1245 A\> C) germline variant will be performed by Sanger sequencing.

    Time frame: Up to 12 months

  6. Correlation Between HSD3B1 (1245C) Variant and SDHEA Levels

    Correlation between HSD3B1 (1245C) variant and SDHEA levels will be reported. The genotyping of the HSD3B1 (1245 A\> C) germline variant will be performed by Sanger sequencing.

    Time frame: Up to 12 months

  7. Correlation Between HSD3B1 (1245C) Variant and Clinical Response

    Correlation between HSD3B1 (1245C) variant and clinical response will be performed by univariate and multivariate analyses.

    Time frame: Up to 12 months

  8. Correlation Between D4A Levels with Testosterone Dosage

    Testosterone ultrasensitive dosages will be performed on participant serum samples. Testosterone dosage will be performed by liquid chromatography coupled with tandem mass spectrometry.

    Time frame: Up to 12 months

  9. Correlation Between D4A Levels with SDHEA Dosage

    SDHEA ultrasensitive dosages will be performed on participant serum samples. Dosage will be performed by liquid chromatography coupled with tandem mass spectrometry.

    Time frame: Up to 12 months

  10. Correlation Between D4A Levels with Clinical Response

    Correlation between D4A levels with clinical response will be performed by univariate and multivariate analyses.

    Time frame: Up to 12 months

07

Study locations

1 site
  • Sociedade Beneficiante de Senhoras - Hospital Sirio Libanes
    São Paulo, 01308901, Brazil
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2020 to primary completion in Nov 2020, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2020
First posted
Feb 13, 2020
StartActual
Mar 19, 2020
Primary completionActual
Nov 16, 2020
CompletionActual
Nov 16, 2020
Last update
Jan 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04268628
Responsible party
Sponsor
First posted
Feb 13, 2020
Start date
Mar 19, 2020
Primary completion
Nov 16, 2020
Completion
Nov 16, 2020
Last update
Jan 3, 2022

Study contacts

Janssen-Cilag Farmaceutica Ltda. Clinical Trial
study director · Janssen-Cilag Farmaceutica Ltda.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion